NN-9500 is a recombinant protein commercialized by Novo Nordisk, with a leading Phase II program in Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to Globaldata, it is involved in 10 clinical trials, of which 5 were completed, 3 are ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of NN-9500s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for NN-9500 is expected to reach an annual total of $9 mn by 2040 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
NN-9500 Overview
NN-9499 is under development for the treatment of alcoholic liver disease, non-alcoholic steatohepatitis. It is administered by subcutaneous route. It is a recombinant protein and fibroblast growth factor 21 analogue.
It was also under development for the treatment of obesity.
Novo Nordisk Overview
Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company with focus on discovering, developing, and manufacturing biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious and chronic conditions including haemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases and obesity. The companys portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for haemophilia; glucagon; and oral antidiabetic agents. The company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.
The company reported revenues of (Danish Krone) DKK232,261 million for the fiscal year ended December 2023 (FY2023), an increase of 31.3% over FY2022. In FY2023, the companys operating margin was 44.2%, compared to an operating margin of 42.3% in FY2022. In FY2023, the company recorded a net margin of 36%, compared to a net margin of 31.4% in FY2022.
The company reported revenues of DKK65,349 million for the first quarter ended March 2024, a decrease of 0.8% over the previous quarter.
For a complete picture of NN-9500s valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.